Analyst ratings can influence market perception and investor sentiment. The reiteration of an Outperform rating and a maintained price target of $50 by RBC Capital suggests a positive outlook for Arrowhead Pharma, which could lead to increased investor confidence and potential upward movement in the stock price in the short term.